Company:  GT BIOPHARMA, INC. (GTBP)
Form Type:  8-K
Filing Date:  9/24/2019 
CIK:  0000109657 
Address:  9350 WILSHIRE BLVD.
SUITE 203
 
City, State, Zip:  BEVERLY HILLS, California 90212 
Telephone:  (800) 304-9888 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$18.00  
Change: 
0.58 (3.33%)  
Trade Time: 
Jun 11  
Market Cap: 
$380.30M
Trade GTBP now with 

© 2021  
Description of Business
We are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based off our proprietary Tri-specific Killer Engager (TriKE(TM)) fusion protein immune cell engager technology platform. Our TriKE platform generate proprietary therapeutics designed to harness and enhance the cancer killing abilities of a patient's own natural killer cells, or NK cells. Once bound to an NK cell, our moieties are designed to enhance the NK cell, and precisely direct it to one or more specifically-targeted proteins expressed on a specific type of cancer cell or virus infected cell, ultimately resulting in the targeted cell's death. TriKE can be designed to target any number of tumor antigens on hematologic malignancies, sarcomas or solid tumors and do not require patient-specific customization.
Register and access this filing in:     
  FORM 8-K
    SECTION 1 BUSINESS AND OPERATIONS
      Item 1.01. Entry into a Material Definitive Agreement.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01 Financial Statements and Exhibits.
    SIGNATURE PAGE
  EXHIBIT 99.1